Discover why Standard Process’ Cultivate symposium aims to close clinical education gaps in whole-food nutrition and reshape healthy aging care for practitioners.
Find out why Oncolytics Biotech’s latest GOBLET cohort 4 data could reshape immunotherapy strategies for third-line anal cancer.
Find out how Actuate Therapeutics’ elraglusib Phase 2 data at ASCO GI 2026 could change first-line treatment strategies for metastatic pancreatic cancer.
ZYUS Life Sciences launches a C$15–16 million LIFE offering to advance cannabinoid drug development and regulatory execution. Find out what it signals.
Find out how Automated Industrial Robotics Inc.’s KAON Automation acquisition strengthens aseptic filling and pharmaceutical manufacturing automation.
Find out how Madrigal Pharmaceuticals is building a multi-mechanism MASH pipeline with ervogastat, a Phase 2 oral DGAT-2 inhibitor.
Find out how a peer-reviewed study shows LEON’s FR-JET modular mixer enabling stable high-concentration mRNA-LNPs with enhanced in vivo activity.
Find out how Polyrizon’s NASARIX branding positions the PL-14 allergy blocker for regulatory progress and future market readiness.
Biofrontera Inc. has confirmed that databases for two of its clinical studies have been formally locked, a procedural milestone that signals the completion of data collection and validation and the transition into final statistical analysis. Although database locks rarely attract the same level of attention as topline efficacy readouts, they represent one of the most […]